Verastem
VSTM
8.27
+0.52
+6.65%
Verastem
US · VSTM
#3468 by market cap
8.27
+0.52
+6.65%
Live - 5344 symbols - heartbeat 283s ago
· 2026-10-08 09:03
Pre-market
8.20
-0.83%
After-hours
8.27
0.00%
- Market cap
- 748.51M
- P/E (TTM)i
- -3.42
- P/Bi
- 14.97
- EPSi
- -3.02
- Div yieldi
- 0.00%
- 52W posi
- 65%
Reader sentiment
Are you bullish or bearish on VSTM?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Weak
- Altman Z-Score is -5.66, below the 1.8 "distress zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +209.14% YoY
Margins
- Gross margin
- 82.86%
- Operating margin
- -550.33%
- Net margin
- -677.59%
Key ratios & quality
- Enterprise valuei
- 621.87M
- Altman Z-Scorei
- -5.66
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 26.72M | 17.46M | 88.52M | 2.05M | 2.60M | 0 | 10.00M | 30.91M |
| Gross profit | 26.13M | 14.65M | 54.77M | -- | -- | 0 | 10.00M | 25.62M |
| Selling & admin expenses | 77.27M | 101.21M | 62.76M | 24.12M | 24.98M | 30.73M | 43.62M | 81.15M |
| Research & development | 43.65M | 45.78M | 41.38M | 39.35M | 50.56M | 61.36M | 81.33M | 114.60M |
| Operating profit | -94.78M | -132.34M | -49.36M | -61.41M | -72.94M | -92.08M | -114.96M | -170.13M |
| Pretax profit | -72.43M | -149.21M | -67.53M | -71.20M | -73.81M | -87.37M | -130.45M | -209.47M |
| Tax | 0 | 0 | 194.00K | -- | 0 | 0 | 185.00K | 0 |
| Net profit | -72.43M | -149.21M | -67.73M | -71.20M | -73.81M | -87.37M | -130.64M | -209.47M |
| Basic EPS | -13 | -24 | -5 | -5 | -5 | -4 | -4 | -3 |
| Diluted EPS | -16.44 | -24.00 | -5.28 | -4.90 | -4.57 | -3.96 | -3.66 | -3.02 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 2.14M | 11.24M | 17.54M | 18.67M | 40.08M |
| Gross profit | 0 | 1.69M | 9.28M | 14.64M | 15.62M | 36.04M |
| Selling & admin expenses | 15.02M | 20.67M | 21.01M | 24.44M | 22.30M | 27.41M |
| Research & development | 29.15M | 24.79M | 28.99M | 31.67M | 38.22M | 41.34M |
| Operating profit | -44.17M | -43.76M | -40.72M | -41.48M | -44.90M | -32.71M |
| Pretax profit | -52.10M | -25.93M | -98.52M | -32.92M | -36.59M | -33.86M |
| Tax | -- | 0 | -- | -- | -- | 816.00K |
| Net profit | -52.10M | -25.93M | -98.52M | -32.92M | -36.59M | -34.67M |
| Basic EPS | -1 | 0 | -1 | 0 | 0 | 0 |
| Diluted EPS | -0.96 | -0.62 | -1.35 | -0.29 | -0.46 | -0.35 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 253.26M | 84.96M | 144.94M | 105.74M | 92.87M | 143.68M | 94.96M | 223.41M |
| Cash & ST investments | 249.65M | 75.51M | 141.23M | 100.26M | 87.89M | 137.13M | 88.82M | 213.80M |
| Inventory | 327.00K | 3.10M | -- | -- | -- | -- | 0 | 1.83M |
| Total assets | 277.24M | 145.05M | 154.35M | 108.66M | 95.05M | 149.72M | 101.54M | 246.44M |
| Total current liabilities | 37.08M | 29.89M | 17.09M | 18.59M | 21.66M | 26.38M | 30.97M | 72.27M |
| Short-term debt | 5.72M | 420.00K | 558.00K | 667.00K | 1.07M | 941.00K | 995.00K | 5.84M |
| Long-term debt | 114.74M | 103.62M | 19.05M | 249.00K | 24.53M | 40.09M | 40.72M | 81.33M |
| Total liabilities | 152,937,000.00 | 137,872,000.00 | 39,075,000.00 | 21,103,000.00 | 47,659,000.00 | 92,344,000.00 | 130,431,000.00 | 189,245,000.00 |
| Total equity | 124.30M | 7.17M | 115.27M | 87.56M | 47.39M | 57.37M | -28.89M | 57.20M |
| Retained earnings | -375.58M | -524.79M | -592.51M | -663.71M | -737.52M | -824.89M | -955.53M | -1.16B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 124.70M | 174.27M | 154.06M | 223.41M | 202.90M | 176.16M |
| Cash & ST investments | 117.57M | 164.32M | 137.71M | 213.80M | 181.68M | 136.35M |
| Inventory | -- | 1.17M | 1.79M | 1.83M | 2.29M | 2.40M |
| Total assets | 131.70M | 196.26M | 176.85M | 246.44M | 227.81M | 206.51M |
| Total current liabilities | 35.62M | 50.36M | 59.71M | 72.27M | 66.85M | 78.13M |
| Short-term debt | 3.03M | 4.18M | 5.10M | 5.84M | 6.29M | 5.94M |
| Long-term debt | 73.50M | 80.54M | 84.37M | 81.33M | 76.87M | 76.27M |
| Total liabilities | 164,131,000.00 | 160,208,000.00 | 192,378,000.00 | 189,245,000.00 | 146,031,000.00 | 156,525,000.00 |
| Total equity | -32.43M | 36.06M | -15.53M | 57.20M | 81.78M | 49.99M |
| Retained earnings | -1.01B | -1.03B | -1.13B | -1.16B | -1.20B | -1.24B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -74.52M | -138.52M | -33.51M | -53.50M | -63.67M | -86.46M | -104.77M | -137.51M |
| Depreciation & amortization | 1.42M | 2.18M | 1.26M | 72.00K | 118.00K | 62.00K | 26.00K | 728.00K |
| Free cash flow | -98.02M | -138.53M | -33.54M | -53.70M | -63.67M | -86.46M | -104.80M | -147.13M |
| Dividends paid | 0 | 0 | 0 | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 105.16M | 0 | 106.06M | 6.72M | 27.35M | 91.42M | 14.22M | 196.98M |
| Ending cash balance | 130.61M | 79.26M | 68.02M | 21.49M | 75.79M | 79.08M | 89.06M | 205.23M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -38.68M | -32.66M | -36.22M | -29.95M | -52.12M | -43.91M |
| Depreciation & amortization | 10.00K | 128.00K | 292.00K | 298.00K | 279.00K | 280.00K |
| Free cash flow | -38.68M | -32.66M | -44.50M | -31.30M | -52.12M | -43.91M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 30.16M | 69.93M | 0 | 96.88M | 0 | 0 |
| Ending cash balance | 117.81M | 164.56M | 137.95M | 205.23M | 165.79M | 136.59M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -79.61 | -226.98 | -110.62 | -70.21 | -109.39 | -166.79 | -917.36 | -1,480.15 |
| ROA %i | -39.47 | -70.67 | -45.24 | -54.14 | -72.47 | -71.39 | -103.99 | -120.39 |
| ROIC %i | -42.87 | -73.99 | -44.81 | -53.74 | -88.25 | -103.17 | -232.09 | -269.33 |
| 5-year avg ROE %i | -67.58 | -102.63 | -112.65 | -118.35 | -119.36 | -136.80 | -274.87 | -548.78 |
| EBIT margin %i | -249.36 | -736.72 | -58.45 | -2,982.37 | -2,760.98 | -- | -1,258.90 | -673.91 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Current ratioi | 6.83 | 2.84 | 8.48 | 5.69 | 4.29 | 5.45 | 3.07 | 3.09 |
| Quick ratioi | 6.74 | 2.61 | 8.28 | 5.42 | 4.06 | 5.20 | 2.87 | 2.96 |
| Debt / assetsi | 43.45 | 74.14 | 14.60 | 2.93 | 28.47 | 27.76 | 41.61 | 35.37 |
| LT debt / equityi | 92.31 | 1,493.06 | 19.07 | 2.87 | 54.85 | 70.79 | -- | 142.19 |
| Interest coveragei | -11.47 | -6.24 | -3.28 | -6.14 | -33.54 | -20.11 | -27.60 | -183.07 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -57.49 | -47.02 | -- | 69.51 | 128.36 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -- | -606.68 | -- | -1,480.15 | -786.15 | -471.16 |
| ROA %i | -116.66 | -110.30 | -159.03 | -120.39 | -107.90 | -100.65 |
| ROIC %i | -- | -184.52 | -- | -269.33 | -186.22 | -160.44 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -1,450.68 | -7,658.96 | -1,786.77 | -673.91 | -388.49 | -228.97 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 3.50 | 3.46 | 2.58 | 3.09 | 3.04 | 2.25 |
| Quick ratioi | 3.31 | 3.31 | 2.42 | 2.96 | 2.87 | 2.12 |
| Debt / assetsi | 58.31 | 43.16 | 50.59 | 35.37 | 37.52 | 40.84 |
| LT debt / equityi | -- | 223.37 | -- | 142.19 | 96.83 | 156.83 |
| Interest coveragei | -40.03 | -60.66 | -127.90 | -183.07 | -145.05 | -135.68 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Business of researching, developing and commercializing drugs for the treatment of patients with100.00%
Quote time 2026-10-08 09:03:15 · For reference only, not investment advice and not tailored to your situation.